Stocks › Drug Manufacturers - Specialty & Generic › EOLS

Evolus EOLS

US equityMarket cap rank #3732Drug Manufacturers - Specialty & Generic

$7.67 −$0.07 (-0.92%)

Market open · Oct 8, 10:00 am ET · After hours $7.74 0.00%

Open$7.68

Prev close$7.74

Day range$7.55 – $7.68

Volume33.2K

Market cap$506.54M

P/E (TTM)–

Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership77.3%+4.14 pts vs. prior quarter

Institutions holding184-1 vs. prior quarter

Insider trades (recent)28 buys / 22 sellsNet buying

Short interest8.37% of floatDays to cover 6.6 · as of 15 Sep 2026

Short-sale volume share21.6%5-day average of daily volume

Short-sale volume as % of daily volume

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$1.89M (7 inflow days, 13 outflow days).

Net flow by order size, last 20 sessions

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 35.6% of shares outstanding.

Largest holders

Timothy Lynch9.73%
Nantahala Capital Management, LLC8.48%
BlackRock7.33%
Soleus Capital Management, L.P.5.27%
Braidwell LP4.78%
Vanguard Capital Management, LLC4.27%
Frazier Life Sciences Management, LP3.98%
Perceptive Advisors LLC3.72%

By investor type

Hedge Fund35.22%
Mutual Fund31.10%
Individual/Insider10.89%
VC/PE Fund7.71%
Public Company2.13%
Private Company0.65%
Government Pension Fund0.19%
Insurance Company0.15%

Reported short interest has fallen from 9.14% to 8.37% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).

Recent institutional activity

Holder	Type	Period	Share change	New stake
Soleus Capital Management, L.P.	Hedge Fund	2026/Q3	+2,657,572	5.3%
Nuveen Asset Management LLC	Insurance Company	2026/Q3	+101,383	0.2%
Point72 Asset Management, L.P.	Hedge Fund	2026/Q3	+1,508,518	2.3%
Perceptive Advisors LLC	VC/PE Fund	2026/Q3	+1,172,423	3.7%
BlackRock	Mutual Fund	2026/Q3	+550,445	7.3%
State Street Global Advisors	Mutual Fund	2026/Q3	+376,504	2.6%
Pinnacle Associates, Ltd.	Mutual Fund	2026/Q3	+328,369	2.3%
Millennium Management LLC	Hedge Fund	2026/Q3	+326,770	2.7%
Assenagon Asset Management S.A.	Mutual Fund	2026/Q3	+310,035	1.4%
Walleye Capital LLC	Hedge Fund	2026/Q3	+253,817	0.4%
Geode Capital Management, LLC	Mutual Fund	2026/Q3	+227,056	2.4%
Wellington Management Group	Mutual Fund	2026/Q3	+169,934	0.3%
KPV Capital Advisors, LP	Hedge Fund	2026/Q3	+150,000	0.2%
Teachers Insurance and Annuity Association-College Retirement Equities Fund	Mutual Fund	2026/Q3	+122,012	0.3%
The Goldman Sachs Group, Inc.	Public Company	2026/Q3	+114,521	1.4%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

Date	Insider	Title	Transaction	Shares	Price	Held after
1 Sep 2026	David Moatazedi	Chief Executive Officer	Open Market Disposition	-105,108	$9.04	361
19 Mar 2026	Rui Avelar	Chief Medical Officer and Head of Research & Development	Automatic Disposition	-3,119	$4.75	272,662
19 Mar 2026	David Moatazedi	Chief Executive Officer	Automatic Disposition	-13,669	$4.75	105,469
16 Mar 2026	Rui Avelar	Chief Medical Officer and Head of Research & Development	Automatic Disposition	-21,192	$4.89	275,781
16 Mar 2026	David Moatazedi	Chief Executive Officer	Automatic Disposition	-49,231	$4.89	119,138
16 Mar 2026	Rui Avelar	Chief Medical Officer and Head of Research & Development	Derivative Exercise and Sale	-8,804	$4.89	275,781
16 Mar 2026	David Moatazedi	Chief Executive Officer	Derivative Exercise and Sale	-67,489	$4.89	119,138
16 Feb 2026	David Gill	Independent Director	Other Acquisition	+45,559	–	52,923
16 Feb 2026	Rui Avelar	Chief Medical Officer and Head of Research & Development	Other Acquisition	+94,913	–	160,705
16 Feb 2026	Rui Avelar	Chief Medical Officer and Head of Research & Development	Other Derivative Acquisition	+94,913	–	94,913
16 Feb 2026	Rui Avelar	Chief Medical Officer and Head of Research & Development	Other Derivative Acquisition	+138,649	$4.39	138,649
16 Feb 2026	Albert White	Independent Director	Other Acquisition	+45,559	–	64,430
16 Feb 2026	Vikram Malik	Chairperson	Other Acquisition	+45,559	–	52,923
16 Feb 2026	Karah Parschauer	Independent Director	Other Acquisition	+45,559	–	52,923
16 Feb 2026	David Moatazedi	Chief Executive Officer	Other Acquisition	+313,212	–	523,081
16 Feb 2026	David Moatazedi	Chief Executive Officer	Other Derivative Acquisition	+457,541	$4.39	457,541
16 Feb 2026	David Moatazedi	Chief Executive Officer	Other Derivative Acquisition	+626,424	–	626,424
16 Feb 2026	Brady Stewart	Independent Director	Other Acquisition	+45,559	–	52,923
16 Feb 2026	Tatjana Mitchell	Chief Financial Officer	Other Acquisition	+121,489	–	226,092
16 Feb 2026	Tatjana Mitchell	Chief Financial Officer	Other Derivative Acquisition	+121,489	–	121,489

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report date	Shares short	% of float	Days to cover
15 Sep 2026	5,530,759	8.4%	6.6
31 Aug 2026	5,368,957	8.1%	5.2
14 Aug 2026	5,853,655	8.9%	4.4
31 Jul 2026	5,568,442	8.5%	8.7
15 Jul 2026	5,905,990	9.0%	7.3
30 Jun 2026	6,018,141	9.1%	7.3

Discussion

No comments yet — be the first to weigh in on EOLS.